Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

A look back at our top stories of 2024 sees them fall into two major themes: promise, and a realignment of expectations. Some illustrate the potential of new, rising technologies—with artificial ...

The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed to replace a patient’s damaged artery following traumatic injuries ...

After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found a sustainable path forward via a merger into privately owned immunology company ...

Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a long-acting challenger to Novartis and Roche’s Xolair. A deal with ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3. The move follows a phase 2 win last ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to ...

The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace of news hasn’t let up since. We’ve seen Big Pharma dive into antibody-drug ...

For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting. And readers have made it easy for us—it’s clear what kind of story ...